cGVHD can impact everything from 
quality of life to mortality

cGVHD can impact everything from quality of life to mortality

cGVHD is the primary cause of nonrelapse mortality in recipients of allogeneic hematopoietic cell transplant1

  • More severe cGVHD is associated with higher mortality2
  • cGVHD is associated with a higher infection rate, and this contributes to increased mortality3

GVHD can significantly impact a patient's daily life

cGVHD impacted the ability of patients to perform basic daily activities.4*

When symptoms were at their worst4:

  • Daily activities, including housework, shopping, and social interaction, were severely impacted
  • 25% of patients were unable to walk 50 feet without rest
  • 68% of patients were unable to walk 900 feet without rest
1/3 of patients had symptoms remain at their worst for at least 1 year.

of patients had symptoms remain at their worst for at least 6 months5

Among employed patients5:

  • 61% took disability leave
  • 59% required reduced work hours
  • 34% left a job
More than 2/3 of respondents (70%) reported a loss of income as a result of cGVHD.

of respondents (71%) reported a loss of income as a result of cGVHD5

The Prezerve™ post-transplant symptom tracker app can help you stay informed about changes in your patients' symptoms and quality of life
Learn about the tracker
The Prezerve post-transplant symptom tracker app logo.
The Prezerve post-transplant symptom tracker app logo.

Empower patients to take

an active role

View education tools

*Based on an Incyte-sponsored cross-sectional online survey administered from May to August 2020 to US patients aged ≥18 years who had cGVHD within the past 5 years. Respondents reported their cGVHD diagnosis, symptoms and impact on ADL when symptoms were at their worst. Symptoms were assessed using the Lee Symptom Scale. The survey also collected information on demographics and employment status of patients.4,5

ADL=activities of daily living; cGVHD=chronic graft-versus-host disease.

References: 1. MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13-21. 2. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. 3. Lee SJ, Flowers MED. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008;134-141. 4. Yu J, Hamilton BK, Turnbull J, et al. Patient-reported symptom burden and impact on daily activities in chronic graft-versus-host disease. Cancer Med. 2023;12(3):3623-3633. 
5. Yu J, Khera N, Turnbull J, et al. Impact of chronic graft-versus-host disease on patient employment, income, and informal caregiver burden: findings from the living with chronic GVHD patient survey. Transplant Cell Ther. 2023;29(7):470.e1-470.e9.